Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Category & Conditions: Cancer
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
ClinicalTrials.gov Identifier (NCT): NCT01909453
Protocol ID: C4221004
Open Plain Language Summary Result:
Click here